Physioxia improves the selectivity of hematopoietic stem cell expansion cultures

Author:

Igarashi Kyomi J.12ORCID,Kucinski Iwo3ORCID,Chan Yan Yi14,Tan Tze-Kai56ORCID,Khoo Hwei Minn7,Kealy David8ORCID,Bhadury Joydeep12ORCID,Hsu Ian7ORCID,Ho Pui Yan14ORCID,Niizuma Kouta12,Hickey John W.56,Nolan Garry P.56,Bridge Katherine S.8ORCID,Czechowicz Agnieszka14,Gottgens Berthold3,Nakauchi Hiromitsu129ORCID,Wilkinson Adam C.17ORCID

Affiliation:

1. 1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA

2. 2Department of Genetics, Stanford University School of Medicine, Stanford, CA

3. 3Wellcome-MRC Cambridge Stem Cell Institute, Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom

4. 4Department of Pediatrics, Stanford University School of Medicine, Stanford, CA

5. 5Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA

6. 6Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA

7. 7MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

8. 8York Biomedical Research Institute, Department of Biology, University of York, United Kingdom

9. 9Division of Stem Cell Therapy, Distinguished Professor Unit, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Abstract

Abstract Hematopoietic stem cells (HSCs) are a rare type of hematopoietic cell that can entirely reconstitute the blood and immune system after transplantation. Allogeneic HSC transplantation (HSCT) is used clinically as a curative therapy for a range of hematolymphoid diseases; however, it remains a high-risk therapy because of its potential side effects, including poor graft function and graft-versus-host disease (GVHD). Ex vivo HSC expansion has been suggested as an approach to improve hematopoietic reconstitution in low-cell dose grafts. Here, we demonstrate that the selectivity of polyvinyl alcohol (PVA)-based mouse HSC cultures can be improved using physioxic culture conditions. Single-cell transcriptomic analysis helped confirm the inhibition of lineage-committed progenitor cells in physioxic cultures. Long-term physioxic expansion also afforded culture-based ex vivo HSC selection from whole bone marrow, spleen, and embryonic tissues. Furthermore, we provide evidence that HSC-selective ex vivo cultures deplete GVHD-causing T cells and that this approach can be combined with genotoxic-free antibody-based conditioning HSCT approaches. Our results offer a simple approach to improve PVA-based HSC cultures and the underlying molecular phenotype, and highlight the potential translational implications of selective HSC expansion systems for allogeneic HSCT.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3